Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand.
The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
Bone remodelling and bone loss are controlled by a balance between the tumour necrosis factor family molecule osteoprotegerin ligand (OPGL) and its decoy receptor osteoprotegerin (OPG). In addition, OPGL regulates lymph node organogenesis, lymphocyte development and interactions between T cells and dendritic cells in the immune system. The OPGL receptor, RANK, is expressed on chondrocytes, osteoclast precursors and mature osteoclasts. OPGL expression in T cells is induced by antigen receptor engagement, which suggests that activated T cells may influence bone metabolism through OPGL and RANK. Here we report that activated T cells can directly trigger osteoclastogenesis through OPGL. Systemic activation of T cells in vivo leads to an OPGL-mediated increase in osteoclastogenesis and bone loss. In a T-cell-dependent model of rat adjuvant arthritis characterized by severe joint inflammation, bone and cartilage destruction and crippling, blocking of OPGL through osteoprotegerin treatment at the onset of disease prevents bone and cartilage destruction but not inflammation. These results show that both systemic and local T-cell activation can lead to OPGL production and subsequent bone loss, and they provide a novel paradigm for T cells as regulators of bone physiology.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“RANKL is produced by numerous cell types including cells of the osteoblast lineage (46,47) and activated T cells (42,48,49).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [49]
In the citing paper
“T Cells express both soluble and membrane-bound forms of RANKL (49,50), and both forms are implicated in focal bone erosions associated with inflammatory arthritis (26,49).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [49]
In the citing paper
“Within the developed immune system, RANKL is expressed by T cells (42), RANK is expressed by dendritic cells (49), and OPG is expressed by B lymphocytes and dendritic cells (4,70).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [49]
In the citing paper
“However, RANK and RANKL knockout mice had normal Peyer's patches and intact splenic architecture (49,62), indicating that the development of lymph nodes and secondary lymphoid organs can be differentially regulated.”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [49]
In the citing paper
“RANKL inhibition via recombinant OPG treatment also results in marked suppression of bone erosions and osteoclasts in several rodent models, including adjuvant arthritis (26,49,177,232,233), collagen-induced arthritis (26,181,233), and TNF-mediated arthritis (136, 234).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [49]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation.
Lacey, D. L., Timms, E., Tan, H.-L., Kelley, M. J., Dunstan, C. R., Burgess, T., Elliott, R., Colombero, A., Elliott, G., Scully, S., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81569-x · Cited by 5,439
Self-citationOsteoprotegerin: a novel secreted protein involved in the regulation of bone density.
Simonet, W. S., Lacey, D. L., Dunstan, C. R., Kelley, M., Chang, M.-S., Lüthy, R., Nguyen, H. Q., Wooden, S., Bennett, L., Boone, T., et al. (1997) · Cell · doi:10.1016/s0092-8674(00)80209-3 · Cited by 5,130
Self-citationOPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph node organogenesis.
Kong, Y.-Y., Yoshida, H., Sarosi, I., Tan, H.-L., Timms, E., Capparelli, C., Morony, S., Oliveira-dos-Santos, A. J., Van, G., Itie, A., et al. (1999) · Nature · doi:10.1038/16852 · Cited by 3,351 · cited 1×
“We show that: (1) p66 is serine phosphorylated upon treatment with hydrogen peroxide (H2O2) or irradiation with ultraviolet light; (2) ablation of p66 enhances cellular resistance to apoptosis induced by H2O2 or ultraviolet light; (3) a serinephosphorylation defective mutant of p66 cannot restore the normal stress res…”
BackgroundSelf-citationRAG-1-deficient mice have no mature B and T lymphocytes
Mombaerts, P., Iacomini, J., Johnson, R. S., Herrup, K., Tonegawa, S., & Papaioannou, V. E. (1992) · Cell · doi:10.1016/0092-8674(92)90030-g · Cited by 2,931
Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4
Waterhouse, P., Penninger, J. M., Timms, E., Wakeham, A., Shahinian, A., Lee, K. P., Thompson, C. B., Griesser, H., & Mak, T. W. (1995) · Science · doi:10.1126/science.270.5238.985 · Cited by 2,766
Self-citationROLE OF CYTOKINES IN RHEUMATOID ARTHRITIS
Feldmann, M., Brennan, F. M., & Maini, R. N. (1996) · Annual Review of Immunology · doi:10.1146/annurev.immunol.14.1.397 · Cited by 2,514
A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function.
Anderson, D. M., Maraskovsky, E., Billingsley, W. L., Dougall, W. C., Tometsko, M. E., Roux, E. R., Teepe, M. C., DuBose, R. F., Cosman, D., & Galibert, L. (1997) · Nature · doi:10.1038/36593 · Cited by 2,290
Kotake, S., Udagawa, N., Takahashi, N., Matsuzaki, K., Itoh, K., Ishiyama, S., Saito, S., Inoue, K., Kamatani, N., Gillespie, M. T., et al. (1999) · Journal of Clinical Investigation · doi:10.1172/jci5703 · Cited by 1,696
Hsu, H., Lacey, D. L., Dunstan, C. R., Solovyev, I., Colombero, A., Timms, E., Tan, H.-L., Elliott, G., Kelley, M. J., Sarosi, I., et al. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.7.3540 · Cited by 1,636
Self-citationWong, B. R., Rho, J., Arron, J., Robinson, E., Orlinick, J., Chao, M., Kalachikov, S., Cayani, E., Bartlett, F. S., Frankel, W. N., et al. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.40.25190 · Cited by 1,042
Cited by
Items 701–800 of 1,007
The osteoimmunology of alveolar bone loss
Tompkins, K. A. (2016) · Connective Tissue Research · doi:10.3109/03008207.2016.1140152 · Cited by 61
Bone Structure, Development and Bone Biology
Safadi, F. F., Barbe, M. F., Abdelmagid, S. M., Rico, M. C., Aswad, R. A., Litvin, J., & Popoff, S. N. (2009) · Humana Press eBooks · doi:10.1007/978-1-59745-347-9_1 · Cited by 122
CD64-Directed Immunotoxin Inhibits Arthritis in a Novel CD64 Transgenic Rat Model
van Vuuren, A. J., van Roon, J. A. G., Walraven, V., Stuij, I., Harmsen, M. C., McLaughlin, P. M. J., van de Winkel, J. G. J., & Thepen, T. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.10.5833 · Cited by 57
“In addition, RANKL regulates lymphocyte development, and augments T cell/ dendritic cell cooperative interactions (17, 18).”
BackgroundBost, K. L., Bento, J. L., Petty, C. C., Schrum, L. W., Hudson, M. C., & Marriott, I. (2001) · Journal of Interferon & Cytokine Research · doi:10.1089/107999001300177484 · Cited by 64
Extraintestinal Manifestations of Inflammatory Bowel Diseases
Kethu, S. R. (2006) · Journal of Clinical Gastroenterology · doi:10.1097/00004836-200607000-00003 · Cited by 57
Hur, Y., Suh, C., Kim, S., & Won, J. (2006) · Journal of Clinical Immunology · doi:10.1007/s10875-006-9057-8 · Cited by 59
Bone loss in inflammatory arthritis: mechanisms and therapeutic approaches with bisphosphonates
Romas, E. (2005) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2005.06.008 · Cited by 58
Osteoprotegerin, an endogenous antiosteoclast factor for protecting bone in rheumatoid arthritis
Bolon, B. N., Shalhoub, V., Kostenuik, P. J., Campagnuolo, G., Morony, S., Boyle, W. J., Zack, D. J., & Feige, U. (2002) · Arthritis & Rheumatism · doi:10.1002/art.10680 · Cited by 63
Self-citationInterference with immune‐cell‐mediated bone resorption in periodontal disease
Han, X., Kawai, T., & Taubman, M. A. (2007) · Periodontology 2000 · doi:10.1111/j.1600-0757.2007.00215.x · Cited by 68
TSG-6 Regulates Bone Remodeling through Inhibition of Osteoblastogenesis and Osteoclast Activation
Mahoney, D. J., Mikecz, K., Ali, T., Mabilleau, G., Benayahu, D., Plaas, A., Milner, C. M., Day, A. J., & Sabokbar, A. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m802138200 · Cited by 54
RANKL as a therapeutic target of rheumatoid arthritis
Tanaka, S., & Tanaka, Y. (2020) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-020-01159-1 · Cited by 59
RANK ligand, RANK, and OPG expression in type II collagen-induced arthritis mouse
Mori, H., Kitazawa, R., Mizuki, S., Nose, M., Maeda, S., & Kitazawa, S. (2002) · Histochemistry and Cell Biology · doi:10.1007/s00418-001-0376-9 · Cited by 58
Advances in bone biology and new treatments for bone loss
Gallagher, J. C. (2008) · Maturitas · doi:10.1016/j.maturitas.2008.04.005 · Cited by 67
Roato, I., Porta, F., Mussa, A., D’Amico, L., Fiore, L., Garelli, D., Spada, M., & Ferracini, R. (2010) · PLoS ONE · doi:10.1371/journal.pone.0014167 · Cited by 58
Wittrant, Y., Théoleyre, S., Couillaud, S., Dunstan, C. R., Heymann, D., & Rédiní, F. (2003) · Experimental Cell Research · doi:10.1016/j.yexcr.2003.10.016 · Cited by 55
Mechanisms of bone loss in rheumatoid arthritis
Findlay, D. M., & Haynes, D. R. (2005) · Modern Rheumatology · doi:10.1007/s10165-005-0412-z · Cited by 58
Joint remodelling in inflammatory disease
Schett, G. A. (2007) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2007.078972 · Cited by 67
Bone Metabolism in SARS-CoV-2 Disease: Possible Osteoimmunology and Gender Implications
Salvio, G., Gianfelice, C., Firmani, F., Lunetti, S., Balercia, G., & Giacchetti, G. (2020) · Clinical Reviews in Bone and Mineral Metabolism · doi:10.1007/s12018-020-09274-3 · Cited by 55
RANKL/RANK as Key Factors for Osteoclast Development and Bone Loss in Arthropathies
Leibbrandt, A., & Penninger, J. M. (2009) · Advances in experimental medicine and biology · doi:10.1007/978-1-4419-0298-6_7 · Cited by 59
Self-citationFocal bone involvement in inflammatory arthritis: the role of IL17
Rossini, M., Viapiana, O., Adami, S., Idolazzi, L., Fracassi, E., & Gatti, D. (2015) · Rheumatology International · doi:10.1007/s00296-015-3387-x · Cited by 59
Li, J., Wang, Q., Yang, R., Zhang, J., Li, X., Zhou, X., & Miao, D. (2016) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3059 · Cited by 56
Self-citationIdiopathic condylar resorption
Mitsimponas, K. T., Mehmet, S., Kennedy, R., & Shakib, K. (2018) · British Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.bjoms.2018.02.016 · Cited by 54
Update on Menopausal Hormone Therapy for Fracture Prevention
Stepan, J. J., Hruskova, H., & Kverka, M. (2019) · Current Osteoporosis Reports · doi:10.1007/s11914-019-00549-3 · Cited by 61
O’Brien, E. A., Williams, J. H. H., & Marshall, M. J. E. (2001) · Bone · doi:10.1016/s8756-3282(00)00431-2 · Cited by 62
Baker, P. J., Garneau, J., Howe, L., & Roopenian, D. C. (2001) · Acta Odontologica Scandinavica · doi:10.1080/00016350152509247 · Cited by 54
Bush, K., Walker, J. S., Lee, C. S., & Kirkham, B. W. (2001) · Clinical & Experimental Immunology · doi:10.1046/j.1365-2249.2001.01469.x · Cited by 56
Andreev, D., Kachler, K., Schett, G. A., & Bözec, A. (2022) · Bone · doi:10.1016/j.bone.2022.116468 · Cited by 64
IL-15 promotes osteoclastogenesis via the PLD pathway in rheumatoid arthritis
Park, M. K., Her, Y., Cho, M. L., Oh, H.-J., Park, E., Kwok, S., Ju, J. H., Park, K. S., Min, D., Kim, H., et al. (2011) · Immunology Letters · doi:10.1016/j.imlet.2011.04.013 · Cited by 54
Tumor Necrosis Factor-α-converting Enzyme (TACE) Levels in Periodontal Diseases
Bostanci, N., Emingil, G., Afacan, B., Han, B., Ilgenli, T., Atilla, G., Hughes, F. J., & Belibasakis, G. N. (2008) · Journal of Dental Research · doi:10.1177/154405910808700311 · Cited by 53
Moran, C. A., Weitzmann, M. N., & Ofotokun, I. (2017) · Current treatment options in infectious diseases/Current treatment options in infectious disease · doi:10.1007/s40506-017-0109-9 · Cited by 59
Cytokine profiles in osteoporosis suggest a proresorptive bias
Azizieh, F. Y., Raghupathy, R., Shehab, D., Al-Jarallah, K. F., & Gupta, R. (2017) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0000000000000885 · Cited by 56
Kanagawa, H., Masuyama, R., Morita, M., Sato, Y., Niki, Y., Kobayashi, T., Katsuyama, E., Fujie, A., Wu, H., Tando, T., et al. (2015) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-015-0702-2 · Cited by 52
Bone Disorders in Human Immunodeficiency Virus Infection
Glesby, M. J. (2003) · Clinical Infectious Diseases · doi:10.1086/375884 · Cited by 53
“is a TNF-family molecule that activates osteoclasts and osteoclast precursors [12, 13].”
BackgroundmTOR Links Tumor Immunity and Bone Metabolism: What are the Clinical Implications?
Irelli, A., Sirufo, M. M., Scipioni, T., Pietro, F. D., Pancotti, A., Ginaldi, L., & Martinis, M. D. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20235841 · Cited by 55
“OPG binds RANKL to prevent its binding to RANK on monocytes [28,29].”
BackgroundWagner, D., & Fahrleitner‐Pammer, A. (2010) · Wiener Medizinische Wochenschrift · doi:10.1007/s10354-010-0818-x · Cited by 60
Forsblad‐d’Elia, H., Mattsson, L., Ohlsson, C., Nordborg, E., & Carlsten, H. (2003) · Arthritis Research & Therapy · doi:10.1186/ar761 · Cited by 54
CTLA‐4Ig–Induced T Cell Anergy Promotes Wnt‐10b Production and Bone Formation in a Mouse Model
Roser‐Page, S., Vikulina, T., Zayzafoon, M., & Weitzmann, M. N. (2014) · Arthritis & Rheumatology · doi:10.1002/art.38319 · Cited by 59
Osteoimmunology in orthodontic tooth movement
Jiang, C., Li, Z., Quan, H., Li, X., Zhao, J., Jiang, C., Wang, Y., Liu, J., Gou, Y., An, S., et al. (2014) · Oral Diseases · doi:10.1111/odi.12273 · Cited by 60
A T Cell View of the Bone Marrow
Bonomo, A. C., Monteiro, A. C., Gonçalves-Silva, T., Cordeiro-Spinetti, E., Galvani, R. G. A., & Balduíno, A. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00184 · Cited by 63
“T-cell-derived RANKL can contribute to bone loss in some pathological conditions, as it was first proposed by Kong and colleagues in a model of inflammatory bone disease (131).”
BackgroundDendritic-cell-derived osteoclasts: a new game changer in bone-resorption-associated diseases
Lapérine, O., Blin‐Wakkach, C., Guicheux, J., Beck-Cormier, S., & Lesclous, P. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.04.022 · Cited by 57
Curcumin diminishes human osteoclastogenesis by inhibition of the signalosome-associated IκB kinase
von Metzler, I., Krebbel, H., Kuckelkorn, U., Heider, U., Jakob, C., Kaiser, M., Fleissner, C., Terpos, E., & Sezer, O. (2008) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-008-0461-8 · Cited by 53
T cell suppression by osteoclasts in vitro
Grassi, F., Manferdini, C., Cattini, L., Piacentini, A., Gabusi, E., Facchini, A., & Lisignoli, G. (2011) · Journal of Cellular Physiology · doi:10.1002/jcp.22411 · Cited by 52
Lessons from animal models of arthritis
van den Berg, W. B. (2002) · Current Rheumatology Reports · doi:10.1007/s11926-002-0070-5 · Cited by 52
Targeting gut microbiota in osteoporosis: impact of the microbial based functional food ingredients
Duffuler, P., Bhullar, K. S., & Wu, J. (2023) · Food Science and Human Wellness · doi:10.26599/fshw.2022.9250001 · Cited by 59
Kumamoto, H., & Ooya, K. (2003) · Journal of Oral Pathology and Medicine · doi:10.1111/j.1600-0714.2004.00204.x · Cited by 52
IL-27 suppresses RANKL expression in CD4+ T cells in part through STAT3
Kamiya, S., Okumura, M., Chiba, Y., Fukawa, T., Nakamura, C., Nimura, N., Mizuguchi, J., Wada, S., & Yoshimoto, T. (2011) · Immunology Letters · doi:10.1016/j.imlet.2011.02.022 · Cited by 55
Impact of the Oral Commensal Flora on Alveolar Bone Homeostasis
Irie, K., Novince, C. M., & Darveau, R. P. (2014) · Journal of Dental Research · doi:10.1177/0022034514540173 · Cited by 68
“While activated T-cells are recognized as the primary cell population expressing supra-physiological levels of RANKL (Kong et al., 1999; Kotake et al., 2001; Weitzmann et al., 2001) and IL-17 (Kotake et al.”
BackgroundZwerina, K., Koenders, M., Hueber, A., Marijnissen, R. J., Baum, W., Heiland, G. R., Zaiss, M., Mclnnes, I., Joosten, L., van den Berg, W., et al. (2012) · European Journal of Immunology · doi:10.1002/eji.201141871 · Cited by 51
Blüml, S., Friedrich, M., Lohmeyer, T., Sahin, E., Saferding, V., Brunner, J. S., Puchner, A., Mandl, P., Niederreiter, B., Smolen, J. S., et al. (2013) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-203486 · Cited by 50
Osteonecrosis of the jaw a new complication related to Ipilimumab
Owosho, A. A., Scordo, M., Yom, S. K., Randazzo, J. D., Chapman, P. B., Huryn, J. M., & Estilo, C. L. (2015) · Oral Oncology · doi:10.1016/j.oraloncology.2015.08.014 · Cited by 51
Fernández-Murga, M. L., Olivares, M., & Sanz, Y. (2020) · Bone · doi:10.1016/j.bone.2020.115580 · Cited by 50
Hormonal changes affect the bone and bone marrow cells in a rat model
Benayahu, D., Shur, I., & Ben‐Eliyahu, S. (2000) · Journal of Cellular Biochemistry · doi:10.1002/1097-4644(20001201)79:3<407::aid-jcb60>3.0.co;2-8 · Cited by 51
Th17 Cells and Rheumatoid Arthritis—From the Standpoint of Osteoclast Differentiation—
Sato, K. (2008) · Allergology International · doi:10.2332/allergolint.r-07-158 · Cited by 50
Are activated T cells regulators of bone metabolism in children with Crohn disease?
Sylvester, F. A., Davis, P. M., Wyzga, N., Hyams, J. S., & Lerer, T. (2006) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2005.12.027 · Cited by 51
Inflammation and Bony Changes at the Temporomandibular Joint
Kacena, M. A., Merrel, G. A., Konda, S. R., Wilson, K. M., Xi, Y., & Horowitz, M. C. (2001) · Cells Tissues Organs · doi:10.1159/000047889 · Cited by 51
“OPG, a naturally occurring, circulating TNF receptor molecule, has been shown to specifically inhibit osteoclast activity and may therefore reduce bone resorption in arthritic joints such as the TMJ [Kong et al., 1999].”
BackgroundØrstavik, R., Haugeberg, G., Uhlig, T., Falch, J. A., Halse, J., Høiseth, A. D., Lilleås, F., & Kvien, T. K. (2003) · Arthritis Care & Research · doi:10.1002/art.11118 · Cited by 52
Jensen, T. S., Hansen, M. S., Jensen, K. E., Pødenphant, J., Hansen, T. M., & Hyldstrup, L. (2005) · Scandinavian Journal of Rheumatology · doi:10.1080/03009740510017986 · Cited by 51
Villareal, D. T., Kotyk, J. J., Armamento‐Villareal, R. C., Kenguva, V., Seaman, P., Shahar, A., Wald, M. J., Kleerekoper, M., & Fontana, L. (2011) · Aging Cell · doi:10.1111/j.1474-9726.2010.00643.x · Cited by 51
“The discovery of the importance of osteoprotegerin and the RANK ligand in modulating osteoclast formation and activity provides further support for the important role that inflammation plays in determining the rate of bone turnover and quality (Kong et al., 1999; Theill et al., 2002; Takayanagi, 2007).”
BackgroundNakamichi, Y., Udagawa, N., Kobayashi, Y., Nakamura, M., Yamamoto, Y., Yamashita, T., Mizoguchi, T., Sato, M., Mogi, M., Penninger, J. M., et al. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.1.192 · Cited by 50
Self-citationYu, H., Du, Y., Zhang, X., Sun, Y., Li, S., Dou, Y., Li, Z., Yuan, H., & Zhao, W. (2014) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2014.08.025 · Cited by 55
The Modulatory Effects of Mesenchymal Stem Cells on Osteoclastogenesis
Sharaf‐Eldin, W. E., Abu-Shahba, N., Mahmoud, M., & El‐Badri, N. (2015) · Stem Cells International · doi:10.1155/2016/1908365 · Cited by 59
RANKL/RANK/OPG: Key Therapeutic Target in Bone Oncology
Ando, K., Mori, K., Rédiní, F., & Heymann, D. (2008) · Current Drug Discovery Technologies · doi:10.2174/157016308785739857 · Cited by 60
Dissecting the multiple myeloma-bone microenvironment reveals new therapeutic opportunities
Shay, G., Hazlehurst, L., & Lynch, C. C. (2015) · Journal of Molecular Medicine · doi:10.1007/s00109-015-1345-4 · Cited by 56
“In contrast, production of interferon gamma (IFN-γ) can inhibit Tcell-mediated osteolysis [75, 76].”
BackgroundFOXO1 Deletion Reduces Dendritic Cell Function and Enhances Susceptibility to Periodontitis
Xiao, W., Dong, G., Pacios, S., Alnammary, M., Barger, L., Wang, Y., Wu, Y., & Graves, D. T. (2015) · American Journal Of Pathology · doi:10.1016/j.ajpath.2014.12.006 · Cited by 50
Ovariectomy‐induced bone loss occurs independently of B cells
Li, Y., Li, A., Yang, X., & Weitzmann, M. N. (2006) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21121 · Cited by 49
“…turnover that leads to bone destruction in animal models of postmenopausal osteoporosis [Cenci et al., 2000, 2003; Roggia et al., 2001; Weitzmannet al., 2002;Toraldo et al., 2003;Gao et al., 2004; Ryan et al., 2005] and in inflammation conditions such as rheumatoid arthritis [Kong et al., 1999].”
BackgroundSeidner, P. (2011) · Pain Physician · doi:10.36076/ppj.2011/14/e427 · Cited by 58
Expression and function of RANK in human monocyte chemotaxis
Mosheimer, B. A., Kaneider, N. C., Feistritzer, C., Sturn, D. H., & Wiedermann, C. J. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20352 · Cited by 50
Bolon, B. N., Campagnuolo, G., & Feige, U. (2002) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-002-8530-7 · Cited by 53
Self-citationTomita, T., Kakiuchi, Y., & Tsao, P. S. (2005) · Arthritis Research & Therapy · doi:10.1186/ar1856 · Cited by 48
Skeletal and extraskeletal actions of denosumab
Sinningen, K., Tsourdi, E. A., Rauner, M., Rachner, T. D., Hamann, C., & Hofbauer, L. C. (2012) · Endocrine · doi:10.1007/s12020-012-9696-x · Cited by 55
Frey, O., Reichel, A., Bonhagen, K., Morawietz, L., Rauchhaus, U., & Kamradt, T. (2010) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2009.123422 · Cited by 48
Multiple moonlighting functions of mycobacterial molecular chaperones
Henderson, B. E., Lund, P. A., & Coates, A. R. M. (2010) · Tuberculosis · doi:10.1016/j.tube.2010.01.004 · Cited by 48
Brucella abortus Invasion of Osteoblasts Inhibits Bone Formation
Scian, R., Barrionuevo, P., Fossati, C. A., Giambartolomei, G. H., & Delpino, M. V. (2012) · Infection and Immunity · doi:10.1128/iai.00208-12 · Cited by 48
Lietman, S. A., Kalinchinko, N., Deng, X., Kohanski, R. A., & Levine, M. A. (2006) · Human Mutation · doi:10.1002/humu.9433 · Cited by 49
“(Hirotani et al. 2004) Moreover, NFATc1 is the most highly induced gene after treatment of murine bone marrow-derived monocyte/macrophage precursor cells with RANKL (receptor activator of NFκB ligand), which stimulates osteoclastogenic differentiation.”
BackgroundDíaz‐Zúñiga, J., Melgar‐Rodríguez, S., Rojas, L., Álvarez, C., Monasterio, G., Carvajal, P., & Vernal, R. (2017) · Journal of Periodontal Research · doi:10.1111/jre.12461 · Cited by 59
Expression of RANKL and OPG in Middle Ear Cholesteatoma Tissue
Jeong, J. H., Park, C. K., Tae, K., Lee, S. H., Shin, D., Kim, K., & Park, Y. (2006) · The Laryngoscope · doi:10.1097/01.mlg.0000224345.59291.da · Cited by 49
Leflunomide-induced peripheral neuropathy: rapid resolution with cholestyramine wash-out
Hill, C. L. (2003) · British journal of rheumatology · doi:10.1093/rheumatology/keg150 · Cited by 47
Pathogenesis of bone lesions in rheumatoid arthritis.
Goldring, S. R., & Gravallese, E. M. (2002) · Current Rheumatology Reports · doi:10.1007/s11926-002-0069-y · Cited by 44
Ulrich‐Vinther, M. (2007) · Acta Orthopaedica · doi:10.1080/17453690610046512 · Cited by 51
Regulation of osteoclasts by membrane-derived lipid mediators
Oikawa, T., Kuroda, Y., & Matsuo, K. (2013) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-012-1238-4 · Cited by 52
Tousen, Y., Matsumoto, Y., Matsumoto, C., Nishide, Y., Nagahata, Y., Kobayashi, I., & Ishimi, Y. (2016) · British Journal Of Nutrition · doi:10.1017/s0007114516001537 · Cited by 52
Hyperbaric oxygen therapy modulates serum OPG/RANKL in femoral head necrosis patients
Vezzani, G., Quartesan, S., Cancellara, P., Camporesi, E. M., Mangar, D., Bernasek, T. L., Dalvi, P. H., Yang, Z., Paoli, A., Rizzato, A., et al. (2017) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2017.1302440 · Cited by 55
The role of stromal cells in inflammatory bone loss
Wehmeyer, C., Pap, T., Buckley, C. D., & Naylor, A. J. (2017) · Clinical & Experimental Immunology · doi:10.1111/cei.12979 · Cited by 50
Li, S., Yin, H., Zhang, K., Wang, T., Yang, Y., Liu, X., Chang, X., Zhang, M., Yan, X., Ren, Y., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-05014-8 · Cited by 46
Immune-bone interplay in the structural damage in rheumatoid arthritis
Komatsu, N., & Takayanagi, H. (2018) · Clinical & Experimental Immunology · doi:10.1111/cei.13188 · Cited by 49
Etiology and Pathogenesis of Rheumatoid Arthritis
Firestein, G. S. (2009) · Elsevier eBooks · doi:10.1016/b978-1-4160-3285-4.10065-8 · Cited by 78
Samelson, E. J., Broe, K. E., Demissie, S., Beck, T., Karasik, D., Kathiresan, S., & Kiel, D. P. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-2492 · Cited by 49
The RANK/RANKL/osteoprotegerin system in rheumatoid arthritis: New insights from animal models
Neumann, E., Gay, S., & Müller‐Ladner, U. (2005) · Arthritis & Rheumatism · doi:10.1002/art.21361 · Cited by 48
Mechanisms modulating inflammatory osteolysis: A review with insights into therapeutic targets
Shi, W., & Siegal, G. P. (2008) · Pathology - Research and Practice · doi:10.1016/j.prp.2008.07.002 · Cited by 50
Cytokine inhibitors in the treatment of rheumatoid arthritis
Gabay, C. (2002) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2.2.135 · Cited by 51
The proliferative human monocyte subpopulation contains osteoclast precursors
Lari, R., Kitchener, P. D., & Hamilton, J. A. (2009) · Arthritis Research & Therapy · doi:10.1186/ar2616 · Cited by 51
Nadhanan, R. R., Mashtoub, S., Su, Y., Scherer, M. A., Howarth, G. S., & Xian, C. J. (2012) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00587.2011 · Cited by 59
Ulrich-Vinther, M., & Andreassen, T. T. (2005) · Calcified Tissue International · doi:10.1007/s00223-004-0126-9 · Cited by 46
“These studies include osteoporosis [4], erosive arthritis [6], humoral hypercalcemia of malignancy [7, 8], experimental bone metastasis [9], and wear debris–induced osteolysis [10, 11].”
BackgroundThe immune factors have complex causal regulation effects on bone mineral density
Cao, R., Yu, X., Xiong, M.-F., Li, X., Deng, F., & Lei, S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.959417 · Cited by 50
Therapeutic targeting of osteoclast function and pathways
Broadhead, M. L., Clark, J. C. M., Dass, C. R., Choong, P., & Myers, D. E. (2011) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2011.546351 · Cited by 50
Brunetti, G., Faienza, M. F., Piacente, L., Ventura, A., Oranger, A., Carbone, C., Benedetto, A. D., Colaianni, G., Gigante, M., Mori, G., et al. (2013) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00535.2012 · Cited by 46
“Numerous scientists have highlighted the interactions between bone and immune cells, and in particular, the role of the T cell in osteoclast formation and activity in many diseases, including 21-OHD, has been highlighted (6, 10, 22).”
BackgroundRaghu, H., Cruz, C., Rewerts, C. L., Frederick, M. D., Thornton, S., Mullins, E. S., Schoenecker, J. G., Degen, J. L., & Flick, M. J. (2014) · Blood · doi:10.1182/blood-2014-08-594754 · Cited by 53
Bone: Another potential target to treat, prevent and predict diabetes
Liu, D., Mosialou, I., & Liu, J. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13330 · Cited by 46
Regulatory mechanisms of sclerostin expression during bone remodeling
Koide, M., & Kobayashi, Y. (2018) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-018-0971-7 · Cited by 50
Current imaging strategies in rheumatoid arthritis.
Zeman, M. N., & Scott, P. J. H. (2012) · Europe PMC (PubMed Central) · Cited by 51
Metadata
- Authors
- Kong, Y.-Y., Feige, U., Sarosi, I., Bolon, B., Tafuri, A., Morony, S., Capparelli, C., Li, J., Elliott, R., McCabe, S., Wong, T., Campagnuolo, G., Moran, E., Bogoch, E. R., Van, G., Nguyen, L. T., Ohashi, P. S., Lacey, D. L., Fish, E., Boyle, W. J., & Penninger, J. M.
- Affiliations
- Amgen (Canada) (CA)
- Amgen (United States) (US)
- St. Michael's Hospital (CA)
- University of Toronto (CA)
- ORCID
- Venue
- Nature
- Published
- 1999-11
- Volume
- 402
- Issue
- 6759
- Pages
- 304-309
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W1677043489
- Cited by
- 1,856
- References
- 24
- Citations by year
- 2026: 17 · 2025: 33 · 2024: 36 · 2023: 33 · 2022: 25 · 2021: 36 · 2020: 47 · 2019: 43 · 2018: 38 · 2017: 59 · 2016: 64 · 2015: 82 · 2014: 80 · 2013: 85 · 2012: 77
- FWCI
- 26.88
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- Cystic Fibrosis Foundation
- U.S. Public Health Service
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies
- Health Sciences › Medicine › Rheumatology › Osteomyelitis and Bone Disorders Research
- Keywords
- osteoprotegerin ligand, osteoprotegerin, RANK, activated T cells, adjuvant-induced arthritis, bone loss, osteoclastogenesis, joint destruction, cartilage destruction, T cell activation, bone remodeling, osteoclasts
- MeSH terms
- Animals, Arthritis, Experimental, Bone and Bones, Bone Resorption, Carrier Proteins, Cartilage, Cells, Cultured, Glycoproteins, Humans, Lymphocyte Activation, Membrane Glycoproteins, Mice, Inbred C57BL, Rats, Inbred Lew, T-Lymphocytes, Receptors, Tumor Necrosis Factor, Receptors, Cytoplasmic and Nuclear, Coculture Techniques, Mice, Rats, Osteoprotegerin, RANK Ligand, Receptor Activator of Nuclear Factor-kappa B
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.